Risperidone compared with olanzapine in a naturalistic clinical study: A cost analysis

Journal of Clinical Psychiatry

Volumn 64, Issue 5, 2003, Pages 589-597

  Taylor, David M ^a   Wright, Tim ^b   Libretto, Susan E ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; ARTICLE; CARDIOTOXICITY; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0038813399     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0515     Document Type: Article

References (42)

1. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-228
2. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics, pt 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85
3. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302
4. Love RC. Novel versus conventional antipsychotic drugs. Pharmacotherapy 1996;16:6s-10s
5. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
6. Høyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402
7. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271-277
8. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
9. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137
10. Tollefson GD, Beasley CM Jr, Tran PV. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
11. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 1999; 15:469-480
12. Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br J Psychiatry 1999;174:15-22
13. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
14. Peuskens J, De Hert M, Jones M. A meta-analysis of efficacy and safety of risperidone and olanzapine [abstract]. Eur Neuropsychopharmacol 2000;10(suppl 3):S317
15. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505
16. Chengappa KNR, Sheth S, Brar JS, et al. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. J Clin Psychiatry 1999;60:373-378
17. Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-868
18. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
19. Rabinowitz J, Bromet EJ, Davidson M. Comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull 2000;27:597-600
20. Conley RR, Mahmoud MD. Risperidone versus olanzapine in people with schizophrenia or schizoaffective disorder: a randomized double-blind study. Am J Psychiatry 2001;158:765-774
21. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
22. Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597-610
23. Sajatovic M, Ramirez LF, Belton J, et al. Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness. Compr Psychiatry 1999;40:198-200
24. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158:266-269
25. Obenchain RL, Johnstone BM. Mixed-model imputations of cost data for early discontinuers from a randomized clinical trial. Drug Inform J 1999;33:191-209
26. Edgell E, Andersen S, Johnstone B, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-579
27. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20:1203-1217
28. Snaterse M, Welch R. A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine. Clin Drug Invest 2000;20:159-164
29. Kasper S, Jones M, Duchesne I. Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:179-187
30. Kasper S, Jones M, Duchesne I. Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:189-196
31. Campbell MJ, Machin D. Medical Statistics: A Common Sense Approach. Chichester, UK: John Wiley & Sons; 1993:156-157
32. World Health Organization. Adverse Reaction Terminology (WHO-ART). Available at: http://www.who-umc.org/pdfs/ardguide.pdf. Accessed April 10, 2003
33. Taylor D, Mace S, Mir S, et al. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000;4:41-46
34. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new reference autipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73
35. Marder SR, Meibach RL. Rispefidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
36. Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4:345-355
37. Lecomte P, De Hert M, van Dijk M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 2000;3:1-11
38. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:253-262
39. Lecompte D, Cookson RF. The economic value of atypical antipsychotics: a comparison of risperidone and olanzapine revisited. Int J Psychiatry Clin Pract 1999;3:3-9
40. Love RC, Conley RR, Kelly DL, et al. A dose-outcome analysis of risperidone. J Clin Psychiatry 1999;60:771-775
41. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63
42. World Health Organization. WHO Drug Information, vol 12. Geneva, Switzerland: World Health Organization; 1998;18-21